Abstract
Cannabis consumption has radically changed over the last several decades. Tetrahydrcannbidiol concentrations are rising, cannabidiol concentrations falling and cannabis is becoming legalized in several regions of the globe. Concerns have been raised as to the impact of increased cannabis exposure within the general population on public health. One of the more serious concerns is the potential relationship between cannabis consumption and psychosis. Research has shown a relationship between increasing cannabis use and increasing psychosis risk. This risk is moderated by other factors such as stress and a family history of psychosis. Within this context, it is important to determine potential markers for future psychosis risk. Genetic and epigenetic research in cannabis and psychosis is in its early stages. One common denominator between cannabis use disorder and psychosis is dopamine dysfunction. Research has begun to link heightened dopamine reactivity with the psychotomimetic effects of cannabis. Studies in COMT and DRD2 polymorphisms have failed to show greater associations with transition to psychosis. Studies of AKT1 have shown slightly more promising results. Genome-wide association studies have recently been published some indicating novel polymorphisms. These may pave the way to alternate hypotheses to explain the missing links between cannabis use and increased risk of psychosis. Such knowledge may eventually lead to new pharmacotherapies in addition to the means of screening patients for psychosis risk.
Keywords: Cannabis use disorder, psychosis, COMT, CNR1, GWAS.
Current Pharmaceutical Design
Title:Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond
Volume: 22 Issue: 42
Author(s): Amine Benyamina, Laurent Karila, Geneviève Lafaye and Lisa Blecha
Affiliation:
Keywords: Cannabis use disorder, psychosis, COMT, CNR1, GWAS.
Abstract: Cannabis consumption has radically changed over the last several decades. Tetrahydrcannbidiol concentrations are rising, cannabidiol concentrations falling and cannabis is becoming legalized in several regions of the globe. Concerns have been raised as to the impact of increased cannabis exposure within the general population on public health. One of the more serious concerns is the potential relationship between cannabis consumption and psychosis. Research has shown a relationship between increasing cannabis use and increasing psychosis risk. This risk is moderated by other factors such as stress and a family history of psychosis. Within this context, it is important to determine potential markers for future psychosis risk. Genetic and epigenetic research in cannabis and psychosis is in its early stages. One common denominator between cannabis use disorder and psychosis is dopamine dysfunction. Research has begun to link heightened dopamine reactivity with the psychotomimetic effects of cannabis. Studies in COMT and DRD2 polymorphisms have failed to show greater associations with transition to psychosis. Studies of AKT1 have shown slightly more promising results. Genome-wide association studies have recently been published some indicating novel polymorphisms. These may pave the way to alternate hypotheses to explain the missing links between cannabis use and increased risk of psychosis. Such knowledge may eventually lead to new pharmacotherapies in addition to the means of screening patients for psychosis risk.
Export Options
About this article
Cite this article as:
Benyamina Amine, Karila Laurent, Lafaye Geneviève and Blecha Lisa, Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond, Current Pharmaceutical Design 2016; 22 (42) . https://dx.doi.org/10.2174/1381612822666160831095707
DOI https://dx.doi.org/10.2174/1381612822666160831095707 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue:“Prion; Mechanism and Function”)
Current Pharmaceutical Biotechnology Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease
Current Alzheimer Research Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry Opioid Receptor Interacting Proteins and the Control of Opioid Signaling
Current Pharmaceutical Design Transformation of UPLC-MS Data Overcomes Extreme Variability in Urine Concentration and Metabolite Fold Change
Current Metabolomics Meet Our Editorial Board Members:
Central Nervous System Agents in Medicinal Chemistry Self-Assembled Nanoparticles of Natural Phytochemicals (Berberine and 3,4,5-Methoxycinnamic Acid) Originated from Traditional Chinese Medicine for Inhibiting Multidrug-Resistant <i>Staphylococcus aureus</i>
Current Drug Delivery At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine Organic Lesions in the Brain MRI of Children with Febrile Seizure
Current Medical Imaging Regulation of the Unfolded Protein Response in Disease: Cellular Stress and microRNAs
Current Immunology Reviews (Discontinued) The Role of Retinoids in the Adult Nervous System and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
Current Topics in Medicinal Chemistry Pharmacological Influencing of The Cholinergic Anti-inflammatory Pathway in Infectious Diseases and Inflammatory Pathologies
Mini-Reviews in Medicinal Chemistry Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia
Current Alzheimer Research Selective Hydrogenation of Aromatic Chloronitro Compounds
Current Organic Chemistry Antioxidant Activity of Plant Phenols: Chemical Mechanisms and Biological Significance
Current Organic Chemistry Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Indandione and Its Derivatives - Chemical Compounds with High Biological Potential
Mini-Reviews in Medicinal Chemistry Lithium Pharmacology and a Potential Role of Lithium on Methamphetamine Abuse and Dependence
Current Drug Research Reviews Role of Cooperativity in Protein Folding and Protein Mosaic Assemblage Relevance for Protein Conformational Diseases
Current Protein & Peptide Science